Selective inducible nitric oxide synthase inhibition attenuates organ dysfunction and elevated endothelin levels in LPS-induced DIC model rats.
We examined the role of nitric oxide (NO) produced by an inducible isoform of NO synthase (iNOS) using N[6]-(iminoethyl)-lysine (L-NIL), a selective iNOS inhibitor, in the rat model of lipopolysaccharide (LPS)-induced disseminated intravascular coagulation (DIC) and investigated changes in organ function, plasma levels of NOX (metabolites of NO) and endothelin. We induced experimental DIC by the sustained infusion of 30 mg kg(-1) LPS for 4 h via the tail vein. We then investigated the effect of L-NIL (6 mg kg(-1), from - 0.5 to 4 h) on LPS-induced DIC. Blood was withdrawn at 4 and 8 h, and all four groups (LPS with or without L-NIL at 4 and 8 h) consisted of eight rats. Three of the animals in the 8-h LPS group died, and we examined blood samples from five rats in this group. None of the other rats died. The LPS-induced elevation of creatinine, alanine aminotransferase, glomerular fibrin deposition and plasminogen activator inhibitor was significantly suppressed by L-NIL coadministration, although L-NIL did not affect the platelet count, fibrinogen concentration or the level of thrombin-antithrombin complex. Moreover, plasma levels of the D-dimer that reflect the lysis of cross-linked fibrin were significantly increased by L-NIL coadministration in the LPS-induced DIC model. Plasma levels of NOX and endothelin were obviously increased by LPS infusion. However, both levels were significantly suppressed in the LPS + L-NIL group, when compared with the LPS group. Although mean arterial pressure (MAP) was significantly decreased between 2 and 8 h compared with the control in the LPS group, this depression was significantly attenuated in the LPS + L-NIL group. Our results suggest that NO induced by iNOS contributes to hypotension (depressed MAP), the progression of hepatic and renal dysfunction, microthrombus deposition and elevated endothelin levels in the rat model of LPS-induced DIC.
Asakura
H
H
Department of Internal Medicine (III), Kanazawa University School of Medicine, Kanazawa, Ishikawa, Japan. hasakura@med3.m.kanazawa-u.ac.jp
Asamura
R
R
Ontachi
Y
Y
Hayashi
T
T
Yamazaki
M
M
Morishita
E
E
Miyamoto
K-I
KI
Nakao
S
S
D000410:Alanine Transaminase / Q000096:biosynthesis; D000818:Animals; D001158:Arteries / Q000473:pathology; D001794:Blood Pressure; D003404:Creatinine / Q000378:metabolism; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy; D016232:Endothelins / Q000096:biosynthesis* / Q000378:metabolism; D004730:Endothelium, Vascular / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005337:Fibrin / Q000096:biosynthesis; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D007668:Kidney / Q000378:metabolism; D008070:Lipopolysaccharides / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008239:Lysine / Q000031:analogs & derivatives* / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D052247:Nitric Oxide Synthase Type II; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis; D011312:Pressure; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D016232:Endothelins; D004791:Enzyme Inhibitors; D005338:Fibrin Fibrinogen Degradation Products; D008070:Lipopolysaccharides; C090663:N(6)-(1-iminoethyl)lysine; D017395:Plasminogen Activator Inhibitor 1; C036309:fibrin fragment D; D009569:Nitric Oxide; D005337:Fibrin; D005340:Fibrinogen; D003404:Creatinine; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D000410:Alanine Transaminase; D008239:Lysine